## **Listing of Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

- 1. (Currently amended) An immunostimulant composition comprising at least one agonist of the Toll-like 7 receptor, wherein the composition additionally comprises an agonist of the Toll-like 4 receptor, wherein said immunostimulant composition potentiates a Th1 type response.
- 2. (Previously presented) The immunostimulant composition as claimed in claim 1, wherein the agonist of the Toll-like 7 receptor is a compound different from the agonist of the Toll-like 4 receptor.
- 3. (Previously presented) The immunostimulant composition as claimed in claim 1, wherein the composition additionally comprises at least one vaccine antigen.
- 4. (Previously presented) The immunostimulant composition of claim 1, wherein the agonist of the Toll-like 7 receptor is an imidazoquinolineamine.
- 5. (Previously presented) The immunostimulant composition as claimed in claim 1, wherein the agonist is a Toll-like 7 receptor agonist which is 4-amino-2-ethoxymethyl- $\alpha$ , $\alpha$ -dimethyl-1-H-imidazo[4,5c]quinoline-1-ethanol.
- 6. (Previously presented) The immunostimulant composition as claimed in claim 1 or 5, wherein the agonist of the Toll-like 4 receptor is ER804057.
- 7. 8. (Cancelled)